Drugs / VAX102
VAX102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00603811 | Sep 2007 → Oct 2008 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00921947 | Jun → Jul 2009 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00921206 Comparator | Jun → Oct 2009 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00921973 Comparator | Jun → Jul 2009 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00921947 ↗ |
| Known as | Flagellin.HuM2e | “VAX102 [Flagellin.HuM2e]” NCT00603811 ↗ |
| Known as | STF2.4×M2e | “STF2.4×M2e (VAX102) is a recombinant fusion protein that links four copies of the ectodomain of influenza virus matrix protein 2 (M2e) antigen to Salmonella typhimurium...” PMID 21203437 ↗ Dec 2010 |
| Modality | Vaccine | “recombinant, inactivated, subunit influenza vaccine” NCT00603811 ↗ |
| Route | Intramuscular | “dose ranging, 2 i.m. doses given 28 days apart” NCT00603811 ↗ |